CancerDrs

Cervical Cancer clinical trials in Minnesota

35 actively recruiting cervical cancer trials at 50 sites across Minnesota.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Minnesota:
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Essentia Health - Deer River Clinic — Deer River, Minnesota
  • Essentia Health Cancer Center — Duluth, Minnesota
  • Miller-Dwan Hospital — Duluth, Minnesota
  • Essentia Health Hibbing Clinic — Hibbing, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Minnesota:
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Coborn Cancer Center at Saint Cloud Hospital — Saint Cloud, Minnesota
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Minnesota:
  • Mayo Clinic in Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Minnesota:
  • Site 155 — Minneapolis, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Minnesota:
  • Minnesota Oncology Hematology, PA ( Site 8003) — Edina, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Minnesota:
  • Mayo Clinic Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…

Sponsor: Mayo Clinic
NCT ID: NCT06915727
Sites in Minnesota:
  • Mayo Clinic in Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Minnesota:
  • Riverwood Healthcare Center — Aitkin, Minnesota
  • Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
  • Essentia Health - Baxter Clinic — Baxter, Minnesota
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Minnesota:
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Minnesota Oncology - Burnsville — Burnsville, Minnesota
  • Mercy Hospital — Coon Rapids, Minnesota
  • Essentia Health - Deer River Clinic — Deer River, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Minnesota:
  • Miller-Dwan Hospital — Duluth, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Minnesota:
  • Local Institution - 2132 — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota:
  • M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Minnesota:
  • Mayo Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Minnesota:
  • Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Minnesota:
  • Mayo Clinic — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard tr…

Sponsor: Mayo Clinic
NCT ID: NCT05541016
Sites in Minnesota:
  • Mayo Clinic in Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Minnesota:
  • Allina Health Cancer Institute - Mercy Hospital — Coon Rapids, Minnesota
  • Allina Health Cancer Institute - Abbott Northwestern Hospital — Minneapolis, Minnesota
  • Allina Health Cancer Institute - United Hospital — Saint Paul, Minnesota
  • Allina Health Cancer Institute — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Minnesota:
  • Exelixis Clinical Site #68 — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Minnesota:
  • M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200 — Minneapolis, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion stu…

Sponsor: SparX Biotech(Jiangsu) Co., Ltd.
NCT ID: NCT06259552
Sites in Minnesota:
  • Mayo Clinic Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Minnesota:
  • Riverwood Healthcare Center — Aitkin, Minnesota
  • Essentia Health - Baxter Clinic — Baxter, Minnesota
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Minnesota Oncology - Burnsville — Burnsville, Minnesota
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Minnesota:
  • Fairview Ridges Hospital — Burnsville, Minnesota
  • Minnesota Oncology - Burnsville — Burnsville, Minnesota
  • Cambridge Medical Center — Cambridge, Minnesota
  • Mercy Hospital — Coon Rapids, Minnesota
  • Fairview Southdale Hospital — Edina, Minnesota
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them fro…

Sponsor: Pfizer
NCT ID: NCT06952660
Sites in Minnesota:
  • M Health Fairview Clinics and Specialty Center — Burnsville, Minnesota
  • M Health Fairview Clinics and Surgery Center — Edina, Minnesota
  • M Health Fairview Clinics and Surgery Center — Maple Grove, Minnesota
  • M Health Fairview St. John's Hospital — Maplewood, Minnesota
  • M Health Fairview Clinics and Surgery Center — Minneapolis, Minnesota
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Minnesota:
  • Massive Bio SYNERGY-AI site — Duluth, Minnesota
View on ClinicalTrials.gov →

Showing 25 of 35 trials with sites in Minnesota. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10